VYNE Therapeutics Inc. (VYNE)

Market Cap	40.42M
Revenue (ttm)	493,000
Net Income (ttm)	-34.15M
Shares Out	14.75M
EPS (ttm)	-0.86
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	67,587
Open	2.750
Previous Close	2.700
Day's Range	2.620 - 2.940
52-Week Range	1.570 - 4.300
Beta	1.28
Analysts	Strong Buy
Price Target	6.88 (+151.1%)
Earnings Date	Mar 7, 2025

About VYNE

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company’s lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company w...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 25, 2018
• Employees: 10
• Stock Exchange: NASDAQ
• Ticker Symbol: VYNE
• Website: https://www.vynetherapeutics.com

Financial Performance

In 2023, VYNE Therapeutics's revenue was $424,000, a decrease of -11.11% compared to the previous year's $477,000. Losses were -$28.60 million, 23.2% more than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for VYNE stock is "Strong Buy." The 12-month stock price forecast is $6.88, which is an increase of 151.10% from the latest price.

Price Target

$6.88

(151.10% upside)

Analyst Consensus: Strong Buy